Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Intravenous or subcutaenous rituximab for FL in the SABRINA study

ASH 2016

Published: 4 Dec 2016

Views: 2057

Rating:

Save

Dr Andrew Davies - University of Southampton, Southampton, UK

Dr Davies speaks with ecancertv at ASH 2016 about the efficacy of treating follicular lymphoma with a fixed subcutaneous dose.

He describes the safety profile of both treatment regimens, with non-inferiority being determined for subcutaneous delivery, though a significant benefit in cost, time and resource demand.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Relapsed Refractory Multiple Myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed Refractory Multiple Myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

Hodgkin’s and non-Hodgkin’s lymphomas (NHL)

Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA

Hodgkin’s and non-Hodgkin’s lymphomas (NHL) ( Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast...

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant...

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

Choosing Wisely to mitigate financial toxicity in cancer care in Africa

Dr Penina Mnandi - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely to mitigate financial toxicity in cancer care in Africa ( Dr Penina Mnandi - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Cancer Services Delivery: Focus on India

Dr Soumitra Datta - Tata Medical Center, Kolkata, India

Cancer Services Delivery: Focus on India ( Dr Soumitra Datta - Tata Medical Center, Kolkata, India )

More from ecancer